Long-term follow-up of people treated with AvenCell CAR-T cells in earlier trials
Tracks long-term safety of CAR-T cells in adults with blood cancers or prostate cancer.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Key facts
- Where
- Berlin, Dresden, Marburg, Munich, and Ulm, GermanySee the 5 sites
- Phase
- Phase 1
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Technische Universitaet DresdenDresden, GermanyTaking people
- Philipps-Universitaet MarburgMarburg, GermanyTaking people
- LMU Klinikum Muenchen AöRMunich, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AvenCell Therapeutics, Inc.
- Trial code
- NCT07474051EU 2025-521717-67-00
- Record updated
- 16 March 2026
- Original description
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or RevCAR platforms.Read full original descriptionShow less
Persistence Evaluation and Response Study for Immunotherapy Safety Tracking of Participants Who Receive an AvenCell CAR-T Cell Therapy
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or RevCAR platforms.
Inclusion: Participant who received an AVC-CAR-T cell therapy within an AVC-sponsored clinical trial; Participant signed written informed consent for the AVC-PERSIST study.
Exclusion: Participant is unable to provide written informed consent; Participant is unable to comply with study requirements in the eyes of the Investigator.